Transcription factors and signaling

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3

Fulciniti M, Yao Y, Perini T, …, Szalat R, …, Munshi NC

Blood Cancer Discovery7(1):129-141DOI: ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3PubMed: ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, …, Szalat R, …, Gallardo M

Cancers13(13):3189DOI: Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple MyelomaPubMed: Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan GJ

Blood132(6):587-597DOI: Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaPubMed: Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

Fulciniti M, Lin CY, Samur MK, …, Szalat RE, …, Munshi NC

Cell Reports25(13):3693-3705.e6DOI: Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple MyelomaPubMed: Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Fulciniti M, Martinez-Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

Blood129(16):2233-2245DOI: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaPubMed: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

P-362 ID2 acts as a novel tumor suppressor in MM by inhibition of TCF3 transcriptional activity

Perini T, Yao Y, Ng JF, …, Szalat R, …, Munshi N

Clinical Lymphoma Myeloma and Leukemia23:S238-S239DOI: P-362 ID2 acts as a novel tumor suppressor in MM by inhibition of TCF3 transcriptional activity

Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu

Yao Y, Perini T, Samur MK, Szalat R, Binder M, Anderson KC, Fulciniti M, Munshi NC

Blood138(Supplement 1):2686-2686DOI: Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu

Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma

Szalat R, Lawlor M, Fulciniti M, …, Munshi N

Clinical Lymphoma Myeloma and Leukemia19(10):e8-e9DOI: Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma

Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma

Perini T, Szalat R, Samur M, …, Munshi N

Clinical Lymphoma Myeloma and Leukemia19(10):e98-e99DOI: Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma

Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma

Ott CJ, Szalat R, Lawlor M, …, Munshi N

Blood132(Supplement 1):1313-1313DOI: Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Perini T, Szalat R, Samur MK, …, Munshi N

Blood132(Supplement 1):60-60DOI: Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Abnormalities in mitochondrial DNA copy number have pathogenetic and prognostic implications in multiple myeloma

Ruiz-Heredia Y, Samur MK, Ortiz-Ruiz A, Fernández RA, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):4378 …

Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

Lin CY, Fulciniti M, Lopez MA, …, Szalat R, …, Munshi N

Blood130(Suppl_1):64-64DOI: Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Li N, Fulciniti M, Lopez MA, …, Szalat R, …, Munshi N

Blood130(Suppl_1):648-648DOI: PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Xu Y, Fulciniti M, Samur MK, Szalat R, Ho M, Lopez MA, Li N, Lin J, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):1755 …

IMPORTANCE OF SERINE/THREONINE KINASE PAK4 IN MULTIPLE MYELOMA: THERAPEUTIC APPLICATIONS OF A NEW CLASS OF INHIBITORS

Joaquin ML, Mariateresa F, Maria L, Stefania O, Rajya LB, Annamaria G, et al.

HAEMATOLOGICA101:21-21

p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

Fulciniti M, Martinez Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

Blood128(22):3302-3302DOI: p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma